Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor-1 concentration in adults from the Veterans Affairs Diabetes Trial

Mark B. Zimering, Robert J. Anderson, Ping Luo, Thomas E. Moritz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Basic fibroblast growth factor (bFGF) is a potent mitogen in endothelial and vascular smooth muscle cells that increases in serum from adults with coronary artery disease and in microalbuminuric type 2 diabetes mellitus. There has been no prior study of plasma bFGF as a possible cardiovascular risk marker in type 2 diabetes mellitus. In this study, we tested for a correlation between log plasma bFGF immunoreactivity (bFGF-IR) and baseline cardiovascular risk factors in a baseline subset of subjects with advanced type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial ([mean] age, 60 years; hemoglobin A1c, 9.5%; diabetes' duration, 11 years). Plasma bFGF-IR was determined with a sensitive, specific, 2-site enzyme-linked immunoassay in 281 patients at the baseline visit. Results were compared with baseline risk factors or baseline medication use. Baseline plasma bFGF-IR ranged from 0 to 141 pg/mL. Log plasma bFGF correlated significantly with non-Hispanic white race (P = .002), waist-hip ratio (P = .002), and plasminogen activator inhibitor-1 concentration (P <.0001). Log plasma bFGF correlated inversely with African American race (P = .0003). In multiple regression analysis, plasminogen activator inhibitor-1 and race were significantly correlated with log plasma bFGF. These results suggest a significant correlation between log plasma bFGF-IR and plasminogen activator inhibitor-1, a marker of hemostatic risk.

Original languageEnglish
Pages (from-to)1563-1569
Number of pages7
JournalMetabolism: Clinical and Experimental
Volume57
Issue number11
DOIs
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Plasminogen Activator Inhibitor 1
Veterans
Fibroblast Growth Factor 2
Type 2 Diabetes Mellitus
Waist-Hip Ratio
Hemostatics
Immunoenzyme Techniques
Vascular Smooth Muscle
Mitogens
African Americans
Smooth Muscle Myocytes
Coronary Artery Disease
Hemoglobins
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor-1 concentration in adults from the Veterans Affairs Diabetes Trial. / Zimering, Mark B.; Anderson, Robert J.; Luo, Ping; Moritz, Thomas E.

In: Metabolism: Clinical and Experimental, Vol. 57, No. 11, 11.2008, p. 1563-1569.

Research output: Contribution to journalArticle

@article{ea49bd6245504a8f86930d501d5046cc,
title = "Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor-1 concentration in adults from the Veterans Affairs Diabetes Trial",
abstract = "Basic fibroblast growth factor (bFGF) is a potent mitogen in endothelial and vascular smooth muscle cells that increases in serum from adults with coronary artery disease and in microalbuminuric type 2 diabetes mellitus. There has been no prior study of plasma bFGF as a possible cardiovascular risk marker in type 2 diabetes mellitus. In this study, we tested for a correlation between log plasma bFGF immunoreactivity (bFGF-IR) and baseline cardiovascular risk factors in a baseline subset of subjects with advanced type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial ([mean] age, 60 years; hemoglobin A1c, 9.5{\%}; diabetes' duration, 11 years). Plasma bFGF-IR was determined with a sensitive, specific, 2-site enzyme-linked immunoassay in 281 patients at the baseline visit. Results were compared with baseline risk factors or baseline medication use. Baseline plasma bFGF-IR ranged from 0 to 141 pg/mL. Log plasma bFGF correlated significantly with non-Hispanic white race (P = .002), waist-hip ratio (P = .002), and plasminogen activator inhibitor-1 concentration (P <.0001). Log plasma bFGF correlated inversely with African American race (P = .0003). In multiple regression analysis, plasminogen activator inhibitor-1 and race were significantly correlated with log plasma bFGF. These results suggest a significant correlation between log plasma bFGF-IR and plasminogen activator inhibitor-1, a marker of hemostatic risk.",
author = "Zimering, {Mark B.} and Anderson, {Robert J.} and Ping Luo and Moritz, {Thomas E.}",
year = "2008",
month = "11",
doi = "10.1016/j.metabol.2008.06.012",
language = "English",
volume = "57",
pages = "1563--1569",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor-1 concentration in adults from the Veterans Affairs Diabetes Trial

AU - Zimering, Mark B.

AU - Anderson, Robert J.

AU - Luo, Ping

AU - Moritz, Thomas E.

PY - 2008/11

Y1 - 2008/11

N2 - Basic fibroblast growth factor (bFGF) is a potent mitogen in endothelial and vascular smooth muscle cells that increases in serum from adults with coronary artery disease and in microalbuminuric type 2 diabetes mellitus. There has been no prior study of plasma bFGF as a possible cardiovascular risk marker in type 2 diabetes mellitus. In this study, we tested for a correlation between log plasma bFGF immunoreactivity (bFGF-IR) and baseline cardiovascular risk factors in a baseline subset of subjects with advanced type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial ([mean] age, 60 years; hemoglobin A1c, 9.5%; diabetes' duration, 11 years). Plasma bFGF-IR was determined with a sensitive, specific, 2-site enzyme-linked immunoassay in 281 patients at the baseline visit. Results were compared with baseline risk factors or baseline medication use. Baseline plasma bFGF-IR ranged from 0 to 141 pg/mL. Log plasma bFGF correlated significantly with non-Hispanic white race (P = .002), waist-hip ratio (P = .002), and plasminogen activator inhibitor-1 concentration (P <.0001). Log plasma bFGF correlated inversely with African American race (P = .0003). In multiple regression analysis, plasminogen activator inhibitor-1 and race were significantly correlated with log plasma bFGF. These results suggest a significant correlation between log plasma bFGF-IR and plasminogen activator inhibitor-1, a marker of hemostatic risk.

AB - Basic fibroblast growth factor (bFGF) is a potent mitogen in endothelial and vascular smooth muscle cells that increases in serum from adults with coronary artery disease and in microalbuminuric type 2 diabetes mellitus. There has been no prior study of plasma bFGF as a possible cardiovascular risk marker in type 2 diabetes mellitus. In this study, we tested for a correlation between log plasma bFGF immunoreactivity (bFGF-IR) and baseline cardiovascular risk factors in a baseline subset of subjects with advanced type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial ([mean] age, 60 years; hemoglobin A1c, 9.5%; diabetes' duration, 11 years). Plasma bFGF-IR was determined with a sensitive, specific, 2-site enzyme-linked immunoassay in 281 patients at the baseline visit. Results were compared with baseline risk factors or baseline medication use. Baseline plasma bFGF-IR ranged from 0 to 141 pg/mL. Log plasma bFGF correlated significantly with non-Hispanic white race (P = .002), waist-hip ratio (P = .002), and plasminogen activator inhibitor-1 concentration (P <.0001). Log plasma bFGF correlated inversely with African American race (P = .0003). In multiple regression analysis, plasminogen activator inhibitor-1 and race were significantly correlated with log plasma bFGF. These results suggest a significant correlation between log plasma bFGF-IR and plasminogen activator inhibitor-1, a marker of hemostatic risk.

UR - http://www.scopus.com/inward/record.url?scp=53649096106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53649096106&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2008.06.012

DO - 10.1016/j.metabol.2008.06.012

M3 - Article

VL - 57

SP - 1563

EP - 1569

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 11

ER -